VistaGen Therapeutics Inc.’s stock (VTGN) continues to rise above its goal

VistaGen Therapeutics Inc. [VTGN] stock prices are up down -0.86% to $0.16 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VTGN shares have lost -15.55% over the last week, with a monthly amount drifted -19.25%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


On 20, September 2022, Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit. In a post published today on Yahoo Finance, Goldie Hawn to lead discussion on supporting mental health around the globe with preeminent C-suite executives, politicians, nonprofit leaders and entrepreneurs on the importance of mental health.

From an analyst’s perspective:

VistaGen Therapeutics Inc. [NASDAQ: VTGN] stock has seen the most recent analyst activity on July 22, 2022, when William Blair downgraded its rating to a Mkt Perform. Previously, Robert W. Baird downgraded its rating to Neutral on July 22, 2022. On July 22, 2022, downgrade downgraded it’s rating to Hold. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $9 on May 20, 2021. Jefferies initiated its recommendation with a Buy and recommended $6 as its price target on February 18, 2021. William Blair upgraded its rating to Outperform for this stock on January 04, 2021. In a note dated June 27, 2018, Maxim Group initiated an Buy rating and iterated a target price of $6 on this stock.

The stock price of VistaGen Therapeutics Inc. [VTGN] has been fluctuating between $0.14 and $2.98 over the past year. Currently, Wall Street analysts expect the stock to reach $2.15 within the next 12 months. VistaGen Therapeutics Inc. [NASDAQ: VTGN] shares were valued at $0.16 at the most recent close of the market. An investor can expect a potential return of 1243.75% based on the average price forecast.

Analyzing the VTGN fundamentals

The most recent quarter, VistaGen Therapeutics Inc. [NASDAQ:VTGN] reported sales of 310.1 million, representing a drop of -25.00%. Gross Margin for this corporation currently stands at +26.49% with Operating Margin at -4308.68%, Pretax Margin comes in at -4306.88%, and Net Margin reading is -4307.19%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1556 points at the first support level, and at 0.1493 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.1676, and for the 2nd resistance point, it is at 0.1733.

VistaGen Therapeutics Inc. [VTGN] reported earnings per share of -$0.09 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.06/share, meaning a difference of $-0.03 and a surprise factor of -50.00%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.05 per share as compared to estimates of -$0.07 per share, a difference of $0.02 representing a surprise of 28.60%.

Ratios To Look Out For

It’s worth pointing out that VistaGen Therapeutics Inc. [NASDAQ:VTGN]’s Current Ratio is 6.20. As well, the Quick Ratio is 12.29, while the Cash Ratio is 11.82. Considering the valuation of this stock, the price to sales ratio is 221.39, the price to book ratio is 3.96.

Transactions by insiders

Insider trading has also been a hot topic recently, with 7 insiders purchasing 1,115,000 shares and 1 selling 60,000 shares in the past 3 months. Recent insider trading involved GIN JERRY B, Director, that happened on Aug 18 when 100000.0 shares were purchased. Director, GIN JERRY B completed a deal on Aug 18 to buy 100000.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Singh Shawn bought 0.6 million shares on Aug 17.